Immutep (ASX: IMM) started a phase 3 clinical trial evaluating a potential combination therapy for first-line metastatic non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
The Tacti-004 trial will assess the company's product candidate eftilagimod alfa in combination with US-based pharmaceutical company MSD's Keytruda therapy and chemotherapy, the filing said.
The trial will compare this regimen with placebo in about 750 patients globally, the filing added. Immutep expects to enroll the first patient into this study during the first quarter of fiscal 2025.
The trial will be conducted at over 150 clinical sites across more than 25 countries. Full approval to start the trial in the UK is expected soon, with additional approvals for multiple countries anticipated in the coming months.
Shares of the biotechnology company fell nearly 1% in recent Tuesday trade.
Price (AUD): $0.33, Change: $-0.003, Percent Change: -0.90%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.